CAPRELSA vandetanib

Drug Class

Kinase inhibitor (VEGFR, EGFR, and RET)

Mechanism

Inhibits VEGFR, EGFR, and RET tyrosine kinases to block angiogenesis, tumor growth, and metastatic dissemination.

Approved Indication

FDA-approved for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

What This Means For Patients

CAPRELSA is a multi-targeted kinase inhibitor for medullary thyroid cancer. Approved by the FDA and EMA, it is available for clinical access under the Hainan Boao pilot-zone special policy.

Regulatory Approvals

• FDA — approved (2011) — label
• EMA — approved (2012) — source

Pivotal Clinical Evidence

• ZETA — Wells et al., J Clin Oncol 2012 (NCT00410761) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa